Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options.
Alejandro Martin Martin Garcia-SanchoAlmudena CaberoNorma C GutiérrezPublished in: Journal of clinical medicine (2023)
Overall, around 40% of patients with diffuse large B-cell lymphoma (DLBCL) have refractory disease or relapse after the first line of treatment. Until relatively recently, the prognosis of patients with relapsed or refractory DLBCL was very poor and treatment options were very limited. In recent years, several novel therapies have been approved that provide more effective options than conventional chemotherapy and that have manageable toxicity profiles. CAR-T cell therapy has become the new standard treatment for patients with refractory or early relapsed DLBCL, based on the positive results of the phase 3 ZUMA-7 and TRANSFORM clinical trials. This review addresses the role of CAR-T therapy and autologous stem cell transplantation in the treatment of these patients and other approved options for patients who are not candidates for transplant, such as the combinations of polatuzumab vedotin with bendamustine and rituximab, and tafasitamab with lenalidomide.
Keyphrases
- diffuse large b cell lymphoma
- epstein barr virus
- stem cell transplantation
- cell therapy
- clinical trial
- acute lymphoblastic leukemia
- hodgkin lymphoma
- end stage renal disease
- acute myeloid leukemia
- multiple myeloma
- mesenchymal stem cells
- chronic kidney disease
- stem cells
- bone marrow
- squamous cell carcinoma
- ejection fraction
- low dose
- peritoneal dialysis
- prognostic factors
- double blind
- patient reported outcomes
- chronic lymphocytic leukemia